RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > Regulatory Manager: What Senior Management Needs to Know About CMC Regulatory Compliance for Biotec

Regulatory Manager: What Senior Management Needs to Know About CMC Regulatory Compliance for Biotech Products Part 1: Initiating Phase 1 Clinical Trials

Posted 01 August 2009

Biotechnology-derived pharmaceuticals are being developed by many companies whose senior management teams have varying degrees of familiarity or experience with the regulatory requirements for these challenging products. A 2006 independent study of the US Food and Drug Administration's (FDA) drug approval review process concluded that biotech startups and first-product biotech companies were especially at risk of failing to achieve their goal of market approval:

 

© 2022 Regulatory Affairs Professionals Society.